OliPass Corporation | Ace Dongbaek Tower 20th Floor, 16-4, 16 Beon-gil, Dongbaek Jungang-ro, Giheung-gu, Yongin, Gyeonggi 17015 Republic of Korea

About OliPass

OliPass Corporation is committed to revolutionize our views of life sciences and bring us great quality of life. OliPass Corporation is committed
to revolutionize our views of life sciences
and bring us great quality of life.

OliPass is constantly working together to find ways
to provide everyone around the world a happy and healthy life.
OliPass is constantly working
together to find ways to provide
everyone around the world
a happy and healthy life.

We are living in remarkable times, in fact when you think about it, over the past 100 years the life expectancy around the globe has almost doubled and we continue, of course, to constantly hope for even greater longevity. But we need to ask ourselves, does this increased longevity lead to a happier life? We all agree that true happiness does not result from just living longer, but also from living well. At OliPass, our mission is to open the door to a new era of healthy and beautiful aging.

Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using our novel PNA based technologies. Thanks to our dedicated team and their hard work, OliPass is now a leading biotech company with OliPass PNA Platform Technology and a growing presence throughout the globe.

At OliPass, scientists from diverse fields are constantly working together to find the cures for all diseases. With our innovative OliPass PNA platform technology, our goal is to make the highest quality of science affordable and accessible, so that everyone around the world can enjoy a happy, healthy life. OliPass is dedicated to providing safe and feasible options for healthy aging.

History
  • 2010’s
    2019
    09Listed on the KOSDAQ
    07OLP-1002’s phase 1 clinical trial was chosen as Korea Drug Development Fund’s government grant project
    2018
    12Strategic research/collaboration agreement with a US-based biotech company
    11OLP-1002 (Pain management OPNA) approved for Phase 1 IND in the UK
    10Awarded grand prize in Bio & New Drug - 4th Industrial Revolution Awards
    05Awarded grand prize in Korea Health Industry Development Industry - 5th BIO KOREA Conference
    01Established subsidiary company (OLIPASS COSMECEUTICALS ASIS PTE. LTD)
    2017
    12Second OPNA structure and design platform technology patent filed with PCT
    07Selected and provided government grant for PCSCK9 hyperlipidemia therapeutic program
    2016
    09Selected and provided government grant for OLP-1002 painkiller program
    2015
    09Established subsidiary company (OLIPASS COSMECEUTICALS)
    04Headquarter moved to Dongbaek Ace Tower, Yongin
    2014
    09Multi-target collaboration agreement with Bristol-Myers Squibb
    2012
    11Company name changed from CIT-Bio to OliPass Corporation
    2010
    09OPNA platform patent entered into PCT national phase
  • 2000’s
    2009
    06Joint research collaboration with EstechPharma for non-opioid painkiller
    03Selected and provided grant from Small and Medium Business Administration
    2008
    05Selected and provided grant from Small and Medium Business Administration
    03Open research facility in Gyeonggi Techno Park
    2007
    08Acquired certificate of venture enterprise
    2006
    11Establishment of CTI-Bio